On August 2, 2026, the US FDA announced approval of a breakthrough gene therapy for a rare genetic disease, driving a collective surge in the US biotech sector. This article reports on the background of the event, market reactions, and industry impact, analyzing subsequent investment opportunities in the biotech sector.
On August 2, 2026, the US FDA announced approval of a breakthrough gene therapy for a rare genetic disease, driving a collective surge in the US biotech sector. This article reports on the background of the event, market reactions, and industry impact, analyzing subsequent investment opportunities in the biotech sector.
